Ardelyx, Inc. (ARDX)
| Market Cap | 1.61B |
| Revenue (ttm) | 407.32M |
| Net Income (ttm) | -61.60M |
| Shares Out | 245.25M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 177.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,594,235 |
| Open | 6.55 |
| Previous Close | 6.63 |
| Day's Range | 6.34 - 6.63 |
| 52-Week Range | 3.21 - 8.40 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 14.67 (+123.97%) |
| Earnings Date | Feb 19, 2026 |
About ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an... [Read more]
Financial Performance
In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price target is $14.67, which is an increase of 123.97% from the latest price.
News
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
DAYTONA BEACH, Fla. and WALTHAM, Mass.
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidan...
Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops
Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs fo...
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Receives New Patent for Tenapanor
WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx: Assessment Of Acquisition Rumors
Ardelyx: Assessment Of Acquisition Rumors
Ardelyx: IBSRELA Momentum Drives Opportunity
Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 mil...
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx: Impressive Q3 Record Growth - Why I Buy
Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; ...
Ardelyx: A Long Overdue Rally
Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supp...
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript
Ardelyx, Inc. ( ARDX) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President,...
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA ® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to...
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting
IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients...
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Com...
Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Citi's Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Offic...